AstraZeneca Proposes Localization of Drug Production in Kazakhstan
At the Kazakhstan Pharmaceutical Forum in Almaty on Feb. 7, Maria Shipuleva, the Country Director of AstraZeneca in Kazakhstan, emphasized that the drug localization project is regarded as one of the company's priority areas. This was reported by the company's press office.
Earlier, the Kazakh Health Ministry signed a roadmap for the drug localization project with several of the world's largest companies, including AstraZeneca.
During the Kazakhstan Pharmaceutical Forum in Almaty, Shipuleva proposed several changes aimed at incentivizing the development of localized production and increasing attractiveness for foreign investors.(Source:astanatimes)
Key suggestions included protecting investors' intellectual property rights through data exclusivity rules for preclinical and clinical studies, as well as restricting counterfeit products' access to government procurement.
Furthermore, the proposal highlighted the potential for compensating costs during technology transfer and signing a preliminary agreement with SK-Pharmacy for purchasing imported drugs subject to localization.
The forum, attended by representatives from the Kazakh Health Ministry, heads of leading pharmaceutical companies, and industry experts, explored proposals to accelerate access to innovative drugs for Kazakh patients.
Based in Cambridge, United Kingdom, AstraZeneca is an innovative global biopharmaceutical company specializing in researching, developing, and commercializing prescription medicines across various therapeutic areas. Operating in over 100 countries, AstraZeneca's innovative medicines are used by millions of patients worldwide.
